> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Intersect PMA for Sinuva
- URL: https://www.fdaweb.com/fda-approves-intersect-pma-for-sinuva/
- Published: 2017-12-11T12:00:00.000Z
- Updated: 2026-09-14T23:06:54.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5140317

FDA has approved an Intersect ENT PMA for the Sinuva (mometasone furoate) Sinus Implant, a new targeted approach to treating recurrent nasal polyp disease in patients who have had previous ethmoid sinus surgery. Inserted during a routine physician office visit, Sinuva expands into the sinus cavity and delivers an anti-inflammatory steroid directly to the site of polyp disease for 90 days. Approval was based on data from a randomized clinical trial that demonstrated a 63% relative reduction in bilateral polyp grade (a measurement of the extent of ethmoid polyp disease) for patients treated with Sinuva compared to control, according to the company.